Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 18 04 2019
accepted: 16 10 2019
pubmed: 28 10 2019
medline: 11 11 2020
entrez: 26 10 2019
Statut: ppublish

Résumé

The dramatic rise in the incidence of thyroid cancer over the last 30 years is largely attributable to the increasing diagnosis of papillary microcarcinomas (mPTCs). Current guidelines endorse an observational management approach in properly selected cases. To evaluate the feasibility of active surveillance in mPTC in Italy, its impact on real life, and to identify risk factors of progression. In 2014 we started a prospective-observational study of active surveillance in mPTC patients. Included patients demonstrated a single Thy4 or Thy5 thyroid nodule, with largest diameter ≤1.3 cm, and no suspicious laterocervical lymph nodes by neck ultrasonography. Of 185 eligible subjects, 50.3% (93/185) enrolled in the observational management protocol while the others opted for surgery and were excluded from this analysis. Enrolled patients were followed with neck ultrasound at 6- to 12-month intervals. Disease progression was defined as the appearance of abnormal lymph nodes or nodule enlargement during follow-up. In these cases, patients were directed to surgery. Three patients (3/93, 3%) showed clinical progression and required surgery. Another 19 patients (19/93, 20%) decided to transition to surgical intervention even though there was no evidence of disease progression. All operated patients had excellent response to initial treatment despite the delayed surgery. Within an Italian medical context, active surveillance appears to be a feasible and safe alternative to immediate surgery in healthy mPTC patients. Only 3% of mPTC demonstrated disease progression during a median follow-up of 19 months (range 6-54) and importantly demonstrated excellent outcomes after surgical intervention in a short-term follow-up.

Identifiants

pubmed: 31652318
pii: 5607347
doi: 10.1210/clinem/dgz113
pmc: PMC8105780
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

JAMA Otolaryngol Head Neck Surg. 2019 Apr 1;145(4):363-370
pubmed: 30703198
Expert Rev Endocrinol Metab. 2018 Mar;13(2):77-85
pubmed: 30058863
Endocr Relat Cancer. 2017 Apr;24(4):197-207
pubmed: 28223365
JAMA Oncol. 2019 Apr 1;5(4):556-564
pubmed: 30543358
Thyroid. 2017 Dec;27(12):1490-1497
pubmed: 29020892
Cancer. 1989 Mar 1;63(5):908-11
pubmed: 2914297
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
N Engl J Med. 2018 Jul 26;379(4):310-312
pubmed: 30044933
Am J Clin Pathol. 2009 Nov;132(5):658-65
pubmed: 19846805
World J Surg. 2010 Jan;34(1):28-35
pubmed: 20020290
Thyroid. 2010 Dec;20(12):1341-9
pubmed: 21034228
World J Surg. 2007 Aug;31(8):1672-6
pubmed: 17571205
JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020
pubmed: 28859191
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Ann Surg Oncol. 2016 Apr;23(4):1361-70
pubmed: 26597365
J Urol. 2018 Dec;200(6):1250-1255
pubmed: 29886089
Thyroid. 2005 Sep;15(9):1041-5
pubmed: 16187912
JAMA. 2017 May 9;317(18):1882-1887
pubmed: 28492905
Diagn Cytopathol. 1996 Jul;15(1):84-9
pubmed: 8807260
World J Surg. 2010 Jun;34(6):1222-31
pubmed: 20066418
J Clin Endocrinol Metab. 1991 Jan;72(1):209-13
pubmed: 1986019
BMJ Open. 2018 Apr 12;8(4):e020298
pubmed: 29654030
N Engl J Med. 2016 Jan 28;374(4):390-2
pubmed: 26816018
Thyroid. 2016 Jan;26(1):150-5
pubmed: 26426735
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2014 Jan;24(1):27-34
pubmed: 24001104
Thyroid. 2003 Apr;13(4):381-7
pubmed: 12804106
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555

Auteurs

Eleonora Molinaro (E)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Maria Cristina Campopiano (MC)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Letizia Pieruzzi (L)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Antonio Matrone (A)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Laura Agate (L)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Valeria Bottici (V)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

David Viola (D)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Virginia Cappagli (V)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Laura Valerio (L)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Carlotta Giani (C)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Luciana Puleo (L)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Loredana Lorusso (L)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Paolo Piaggi (P)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Liborio Torregrossa (L)

Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy.

Fulvio Basolo (F)

Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa, Italy.

Paolo Vitti (P)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

R Michael Tuttle (RM)

Endocrinology Service, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.

Rossella Elisei (R)

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH